Seagen (SGEN) Stock Price, News & Analysis

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGEN, but not buy additional shares or sell existing shares.
View SGEN analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 12-month price targets for Seagen's shares. Their SGEN share price targets range from $229.00 to $229.00. On average, they predict the company's stock price to reach $229.00 in the next year. This suggests a possible upside of 0.1% from the stock's current price.
View analysts price targets for SGEN or view top-rated stocks among Wall Street analysts.

Seagen Inc. (NASDAQ:SGEN) issued its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by $0.33. The biotechnology company earned $648.65 million during the quarter, compared to analyst estimates of $635.10 million. Seagen had a negative net margin of 32.61% and a negative trailing twelve-month return on equity of 28.06%. The business's revenue was up 27.1% on a year-over-year basis. During the same period last year, the firm earned ($1.03) EPS.

ETFs with the largest weight of Seagen (NASDAQ:SGEN) stock in their portfolio include VanEck Biotech ETF (BBH), Invesco Nasdaq Biotechnology ETF (IBBQ), First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Biotechnology ETF (IBB), Principal Healthcare Innovators ETF (BTEC), Goldman Sachs Future Health Care Equity ETF (GDOC), ProShares Ultra Nasdaq Biotechnology (BIB) and IQ U.S. Mid Cap R&D Leaders ETF (MRND).

107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).